Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study

Journal of Thrombosis and Thrombolysis, Feb 2017

Low-molecular weight heparin (LMWH) has been the standard of care for treatment of venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was approved in 2012 for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT), but no prior studies have been reported specifically evaluating the efficacy and safety of rivaroxaban for cancer-associated thrombosis (CAT). Under a Quality Assessment Initiative (QAI), we established a Clinical Pathway to guide rivaroxaban use for CAT and now report a validation analysis of our first 200 patients. A 200 patient cohort with CAT (PE or symptomatic, proximal DVT), whose full course of anticoagulation was with rivaroxaban, were accrued. In competing risk analysis, primary endpoints at 6 months included new or recurrent PE or symptomatic proximal lower extremity DVT, major bleeding, clinically-relevant non-major bleeding leading to discontinuation of rivaroxaban, or death. In competing risk analysis, the 6 months cumulative incidence of new or recurrent VTE was 4.4 % (95 % CI = 1.4–7.4 %), major bleeding was 2.2 % (95 % CI = 0−4.2 %) and all-cause mortality 17.6 % (95 % CI = 11.7–23.0 %). In this cohort of 200 patients with active cancer and CAT the rates of new or recurrent VTE and major bleeding were comparable to the cancer subgroup analysis from the EINSTEIN studies. The results of our Clinical Pathway provide guidance on Rivaroxaban use for treatment of CAT, and suggest that safety and efficacy is preserved, compared with past-published experience with LMWH.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

http://link.springer.com/content/pdf/10.1007%2Fs11239-016-1429-1.pdf

Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study

hTromb hTe fo nad rpoximal aws a fo a edp iwth ot ro nig ochrt noi Electr roaly ot lis W iwth ta hte htrombsi ot ewight fo ugide acner aws rok Y ubt iwth olwer fo fo on xobn riva hte htromb ta ro ahs tsud douci Intr aptien evnous a i e s h a v e b e e n r e p o r t e d s p e c i f i c a l l y e v a l u a t i n g t h e e f f i c a c y f o r a n d n o w r e p o r t a v a l i d a t i o n a n a l y s i s o f o u r f i r s t TVE IENST yb ODI; aCncer; eKywords; i IC 9(5 i n g n o n t h a t s a f e t y a n d e f f i c a c y i s p r e s e r v e d , c o p a r e d i t h p a s t s h o e d s u p e r i o r e f f i c a c y o f l o o l e c u l a r e i g h t h e p a r i n n o t p r o v i d e s u f f i c i e n t g u i d a n c e f o r u s e o f r i v a r o x a b a n i n t h e I I t r i a l s d i d n o t a d d r e s s t h e s p e c i f i c s i t u a t i o n s I n i t i a t i v e . h e p r e s p e c i f i e d g o a l a s t o t r a c k a n i n i t i a l c o h o r t e i d e n t i f i e d t h e i n i t i a l 2 0 0 p a t i e n t s h o h a d s u s t a i n e d a n k e y o r d e r e f i r s t i d e n t i f i e d b y a n a u t o a t e d t e x t s e a r c h i n c l u d e d r e c u r r e n t ( d e f i n i t i o n d e r i v e d f r o t h e o n e ] ) , a j o r b l e e d i n g ( a s d e f i n e d b y t h e a n d a n y s i g n i f i c a n t d r u g i n t e r a c t i o n a l l c o n s t i t u t e d r e l a t i v e t h r o b o c y t o p e n i a , a n d t r a n s i e n t o r g a n d y s f u n c t i o n . u r t h e r , o d i f i e d i n 1 2 e p i s o d e s . n e p a t i e n t e x p e r i e n c e d , s i g n i f i c a n t l o s s o f e f f i c a c y . u r t h e r s u p p o r t f o r t h e l i n i c a l rh i s i s t h e f i r s t r e p o r t e d p r o s p e c t i v e c o h o r t s t u d y o f r i v a o x a b a n t h e r a p y , s p e c i f i c a l l y t a r g e t i n g . I n t h i s c o h o r t o f n i g d e l w o n k c A s c n r e f i d , y g l d o h t e m n a b x o a v i r l i s h t h e s a f e t y , e f f i c a c y a n d c o p a r a b i l i t y t o a , t h e b l e e d i n g ( 2 ) t o o u r n e f i n d i n g s y s i s o f t r e a t e n t o f i t h a p i x a b a n i n t h e I LCOT S c i e n t i f i c f f a i r s , L L . n o t a p p e a r t o b e e v i d e n c e o f l o s s o f s a f e t y o r e f f i c a c y b y u s e t r i b u t e d t o d e v e l o p e n t o f t h e l i n i c a l P a t h a y , s p e c i f i c a l l y r e g a r d i n g F , P r i n s , a s k o b E , S e g e r s , e r h a e P , e l l s P , g n e l l i o u n a e a u x , o h e n , a v i d s o n L , P i o v e l l a F , S c h e l e c o u s u s , J a c o b s o n F , i n a r E , h l u s k y J , e r h a e P , a v i d s o n L , i s s e l i t z F , a l l u s S , a s k o b E , S c h e l l o n g 1 . h o r a n a , F r a n c i s , u l a k o v a E , u d e r e r , L y a n u l a t i o n o f t h e S c i e n t i f i c a n d S t a n d a r d i z a t i o n o i t t e e o f t h e e f i n i t i o n o f a j o r b l e e d i n g i n c l i n i c a l i n v e s t i g a t i o n s o f a n t i h e i c k l e s F , J u l i a n J , a l e y S , o v a c s J , e n t , a n d o 1 5 . F r a n c i s , e s s l e r , o l d h a b e r S Z , o v a c s J , o n r e a l 5 . u l l , P i n e o F , r a n t F , a h F , u r k e e a r o n g 7 . 2 0 1 6 S P r u g P r i c i n g F i l e s e d i c a r e F e e f o r S e r v i c e P a r t r u g s / c r P a r t r u g v g S a l e s P r i c e / 2 0 1 6 S P F i l e s . h t l f r o t h e P L I F t r i a l . J T h r o b a e o s t 1 3 ( 1 2 ) : 2 1 8 7 – 2 1 9 1 . E r i k s s o n , a a n s t r a , S c h n e e J o l d h a b e r S Z E E olng 21. 21 ( 4 ): 30 - 7 .


This is a preview of a remote PDF: http://link.springer.com/content/pdf/10.1007%2Fs11239-016-1429-1.pdf

Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study, Journal of Thrombosis and Thrombolysis, 2017, DOI: 10.1007/s11239-016-1429-1